Citations

Clear

187 citation(s) found for "Ha, Gavin".

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
Zarif, Talal El , Pond, Gregory R. , Zhuang, Tony , Master, Viraj A. , Nazha, Bassel , Niglio, Scot A. , Simon, Nicholas I. , Hahn, Andrew W. , Pettaway, Curtis A. , Tu, Shi‐Ming, Abdel‐Wahab, Noha , Velev, Maud , Flippot, Ronan , Maruzzo, Marco , Yang, Yuanquan , Rodriguez, Pablo Alvarez, Castellano, Daniel , Velasco, Guillermo de , Roviello, Giandomenico , Antonuzzo, Lorenzo , McKay, Rana R. , Hui, Gavin , Drakaki, Alexandra , Glover, Michael , Khaki, Ali Raza , El‐Am, Edward , Patel, Vaibhav G. , Piedra, A. , Gernone, Angela , Davis, Nancy B. , Matthews, Harrison, Giudice, Giulia Claire , Farolfi, Alberto , Milowsky, Matthew I. , Appleman, Leonard J. , Freeman, Dory , Sonpavde, Guru , El Zarif, Talal , Nazha, Bassel , Hahn, Andrew W , Antonuzzo, Lorenzo , Khaki, Ali Raza , El-Am, Edward , Appleman, Leonard , Choueiri, Toni K , Spiess, Philippe E , Necchi, Andrea , Sonpavde, Guru , Pond, Gregory Russell , Nassar, Amin H. , Tu, Shi‐Ming , Buti, Sebastiano , Mittra, Arjun , Gheeya, Jinesh , Vincenzi, Bruno , Cortellini, Alessio , Drakaki, Alexandra , Adra, Nabil , Mouhieddine, Tarek H. , Harrison, Michael R. , Kanesvaran, Ravindran , Barata, Pedro C. , Lee, Jae‐Lyun , Stahlfeld, Charlotte N. , Kim, Joseph W. , Choueiri, Toni K. , Spiess, Philippe E. , Necchi, Andrea , Apolo, Andrea B

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 11, 2023 | Volume: 115 | Issue: 12 | Pages: 1605-1615

10.1093/jnci/djad155 | PMID 37563779 Get It

Abstract Background Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors. Methods This retrospective study included patients with locally advanced or metastatic penile squamous cell carcinoma receiving immune checkpoint inhibitors between 2015 and 2022 across 24 centers in the United States, Europe, and Asia. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. Objective response rates were determined per Response Evaluation Criteria in Solid Tumours 1.1 criteria. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events, version 5.0. Two-sided statistical tests were used for comparisons. Results Among 92 patients, 8 (8.7%) were Asian, 6 (6.5%) were Black, and 24 (29%) were Hispanic and/or Latinx. Median (interquartile range) age was 62 (53-70) years. In all, 83 (90%) had metastatic penile squamous cell carcinoma, and 74 (80%) had received at least second-line treatment. Most patients received pembrolizumab monotherapy (n = 26 [28%]), combination nivolumab-ipilimumab with or without multitargeted tyrosine kinase inhibitors (n = 23 [25%]), or nivolumab (n = 16 [17%]) or cemiplimab (n = 15 [16%]) monotherapies. Median overall and progression-free survival were 9.8 months (95% confidence interval = 7.7 to 12.8 months) and 3.2 months (95% confidence interval = 2.5 to 4.2 months), respectively. The objective response rate was 13% (n = 11/85) in the overall cohort and 35% (n = 7/20) in patients with lymph node–only metastases. Visceral metastases, Eastern Cooperative Oncology Group (ECOG) performance status of 1 or higher, and a higher neutrophil/lymphocyte ratio were associated with worse overall survival. Treatment-related adverse events occurred in 27 (29%) patients, and 9.8% (n = 9) of the events were grade 3 or higher. Conclusions Immune checkpoint inhibitors are active in a subset of patients with penile squamous cell carcinoma. Future translational studies are warranted to identify patients more likely to derive clinical benefit from immune checkpoint inhibitors.
New Horizons in cellular senescence for clinicians
Witham, Miles D. , Granic, Antoneta , Passos, João F. , Sayer, Avan Aihie , Passos, João F , Miwa, Satomi , Richardson, Gavin D.

Mayo Clinic

Age and Ageing | July 19, 2023 | Volume: 52 | Issue: 7 | Pages: No page available

10.1093/ageing/afad127 | PMID 37466640 Get It

Abstract Cellular senescence has emerged as a fundamental biological mechanism underpinning the ageing process and has been implicated in the pathogenesis of an increasing number of age-related conditions. Cellular senescence is a cell fate originally defined as an irreversible loss of replicative potential although it is now clear that it can be induced by a variety of mechanisms independent of replication and telomere attrition. The drivers include a persistent DNA damage response causing multiple alterations in cellular function. Senescent cells secrete a range of mediators that drive chronic inflammation and can convert other cells to the senescent state—the senescence-associated secretory phenotype. Much research to date has been conducted in animal models, but it is now clear that senescent cells accompany ageing in humans and their presence is an important driver of disease across systems. Proof-of-concept work suggests that preventing or reversing senescence may be a viable strategy to counteract human ageing and age-related disease. Possible interventions include exercise, nutrition and senolytics/senostatic drugs although there are a number of potential limitations to the use of senotherapeutics. These interventions are generally tested for single-organ conditions, but the real power of this approach is the potential to tackle multiple age-related conditions. The litmus test for this exciting new class of therapies, however, will be whether they can improve healthy life expectancy rather than merely extending lifespan. The outcomes measured in clinical studies need to reflect these aims if senotherapeutics are to gain the trust of clinicians, patients and the public.
BS5 Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction
Redgrave, Rachael E. , Dookun, Emily , Booth, Laura , Folaranmi, Omowumi, Tual‐Chalot, Simon , Gill, Jason H. , Owens, W. Andrew , Spyridopoulos, Ioakim , Passos, João F. , Richardson, Gavin D.

Mayo Clinic

Basic Science | July 17, 2023 | Volume: No volume available | Issue: No issue available | Pages: A249.1-A249

10.1136/heartjnl-2023-bcs.219 Get It

Semiautomated approach focused on new genomic information results in time and effort- efficient reannotation of negative exome data
Ferrer, Alejandro Tiana, Olson, Rory J. , Meiners, Michael A., Schultz‐Rogers, Laura , Cousin, Margot A. , Williams, Megan, Pichurin, Pavel N. , Deyle, David R. , Gavrilova, Ralitza H. , Wierenga, Klass J., Lanpher, Brendan C. , Babovic‐Vuksanovic, Dusica , Vitek, Carolyn R. Rohrer , McAllister, Tammy M., Wick, Myra , Klee, Eric W. , Ferrer, Alejandro, Duffy, Patrick Emmet , Macke, Erica L. , Safgren, Stephanie L. , Morales‐Rosado, Joel A. , Oliver, Gavin R. , Rider, David, Williams, Megan, Morava, Éva , Dhamija, Radhika , Kaiwar, Charu , Schimmenti, Lisa A. , Lazaridis, Konstantinos N. , Vairo, Filippo Pinto e

Mayo Clinic

No container title available | July 14, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3146571/v1 Get It

Abstract Introduction: Most rare disease patients (75 − 50%) undergoing genomic sequencing remain unsolved, often due to lack of information about variants identified. Data review over time can leverage novel information regarding disease-causing variants and genes, increasing this diagnostic yield. However, time and resource constraints have limited reanalysis of genetic data in clinical laboratories setting. We developed RENEW, (REannotation of NEgative WES/WGS) an automated reannotation procedure that uses relevant new information in on-line genetic databases to enable rapid review of genetic findings. Methods We tested RENEW in an unselected cohort of 1,066 undiagnosed cases from the Mayo Clinic Center for Individualized Medicine using new information in ClinVar, HGMD and OMIM between the date of previous analysis/testing and April of 2022. Results 5,741 variants prioritized by RENEW were rapidly reviewed by variant interpretation specialists. Mean analysis time was approximately 20 seconds per variant (32 hours total time). Reviewed cases were classified as: 879 (93.0%) undiagnosed, 63 (6.6%) putatively diagnosed, and 4 (0.4%) definitively diagnosed. Discussion New strategies are needed to enable efficient review of genomic findings in unsolved cases. We report on a fast and practical approach to address this need and improve overall diagnostic success in patient testing through a recurrent reannotation process.
Efficacy of Selective Laser Trabeculoplasty in Patients on Systemic Immunosuppressive Therapy
Kaplan, Tyler M., Hammer, Jon D. , Kohli, D. R., Pacheco, Johann M., Hodge, David O. , Khanna, Cheryl L. , Sit, Arthur J. , Roddy, Gavin W. , Kohli, Darrel, Sit, Arthur J

Mayo Clinic

Journal of Glaucoma | July 5, 2023 | Volume: 32 | Issue: 9 | Pages: 762-768

10.1097/ijg.0000000000002259 | PMID 37406302 Get It

Précis: When comparing patients on systemic immunosuppressive therapy to those without, there was no difference in intraocular pressure (IOP) early after SLT; however, at 1 year following SLT, IOP was higher in the immunosuppression group compared with controls. Purpose: To determine whether patients taking systemic immunosuppressive medications have a different IOP-lowering response to selective laser trabeculoplasty (SLT) compared with a control group of patients. Methods: All patients who underwent SLT at Mayo Clinic 2017–2021 were identified. Patients on systemic immunosuppressive medications at the time of SLT were compared with control patients not receiving systemic immunosuppressive medications. The primary endpoints of this study were the percentage IOP reduction at 1 to 2, 3 to 6, and 12 months. Additional analyses included the percentage of patients who did not require additional therapy at each time point. Results: There were 108 eyes of 72 patients that underwent SLT in the immunosuppressed group and 1997 eyes of 1417 patients in the control group. There was no significant difference in age-adjusted change in IOP between groups at the first postoperative visit 1 to 2 months following SLT (−18.8±20.7% vs. −16.0±16.5%, P=0.256) or 3–6 months following SLT (−15.2±21.6% vs. −18.3±23.2%, P=0.062). However, at 12 months following SLT, the IOP reduction in the immunosuppressive therapy group was significantly less compared with the control group (−15.1±21.2% vs. −20.3±22.9%, P=0.045). There was no difference between groups in the number of additional treatments during the study intervals. Conclusion: Patients in the systemic immunosuppressive therapy group showed equivalent early IOP-lowering after SLT compared with a control group, but the treatment response was diminished at 1 year. Further studies investigating IOP regulation after SLT in immunosuppressed patients are needed.
Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.
Nassar, Amin, Zarif, Talal El , Denu, Ryan A., Goodman, Rachel , Neilan, Tomas G. , Haykal, Tarek , Kojima, Yuji, Trevino, Alexandra , Hui, Gavin , El‐Am, Edward , Choudhary, Arrush, Grynberg, Shirly , Naqash, Abdul Rafeh , Naqash, Abdul Rafeh , Goodman, Rachel S , Grynberg, Shirly , Nassar, Amin H. , Alaiwi, Sarah Abou , Hayek, Salim S. , Woodford, Rachel , Tandon, Ankita, Mittra, Arjun , Baena, Javier , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 2653-2653

10.1200/jco.2023.41.16_suppl.2653 Get It

2653 Background: Given underlying differences in the tumor microenvironment across metastatic sites, ICIs demonstrate variable efficacy depending on sites of met involvement. Data on the safety and outcomes of pts on ICIs with cardiac mets are limited. Methods: In an international multi-center retrospective study, pts with solid tumors and baseline mets to the heart who had received ≥1 cycle of ICIs were included. Immune-related adverse events (irAEs) were graded per CTCAE v5.0. Objective response rates (ORR) were evaluated by RECIST1.1 when available. Median overall survival (mOS) and median progression-free survival (mPFS) were calculated from time of ICI initiation using the Kaplan-Meier method. Results: 110 pts across 20 institutions were identified with a median follow-up of 36 (95% CI 26-51) months. Melanoma (38%, n=42) and non-small cell lung cancer (NSCLC, 24%, n=26) were the most common cancers. Median age at ICI initiation was 65 (IQR: 59-75) years and 29% (n=26) received combination ICI therapy with anti-PD1 and anti-CTLA4. Overall, 62% (n=68) received ICIs as 1st line. The mets were mostly located in the atria (37%, n=41) and ventricles (35%, n=39). At ICI initiation, 21% (n=23) had a cardiac thrombus. Of 78 pts with available echocardiographic data at time of ICI initiation, the mean ejection fraction was 61+/- 7.1%. Cardiology referrals and cardiac MRIs since time of cancer diagnosis were completed on 53% (n=58) and 47% (n=52) of pts, respectively. Overall, 36.4% (n=40) of pts had cardiac complications from the mets, including arrhythmias (13%, n=14), arterial/venous emboli (3.6%, n=4), and cardiac tamponade (2.7%, n=3). For NSCLC, ORR, mPFS (95% CI), and mOS (95% CI) were 23%, 4.4 months (3.0-7.5), and 9.9 months (5.9-14.7), respectively. For melanoma, ORR, mPFS, and mOS were 35.7%, 9.1 months (5.2-20), and 29 months (14-58), respectively. Cardiac met ORRs for NSCLC and melanoma were 27% and 43%, respectively. 74% (N=71/96) of pts with evaluable response data had concordant response in the burden of overall disease and cardiac disease. IrAEs are shown. Conclusions: Although cardiac mets are frequently associated with cardiac complications, ICIs demonstrate meaningful efficacy with no overtly concerning safety signals. Close to three-quarter of pts have concordant response in the overall disease and cardiac disease burden. Multi-disciplinary approach involving cardiologists and oncologists need to be implemented to appropriately manage pts with cardiac mets. [Table: see text]
In vivo KCNQ1-suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome
Bains, Sarina , Alerni, Nicolò , Tester, David J. , Christoforou, Nicolas , Louradour, Julien , Jürgensen, Jan Steffen, Zehender, Manfred, Brunner, Michael, Brooks, Gavin, Ackerman, Michael J. , Giammarino, Lucilla , Nimani, Saranda , Bains, S, Jurgensen, J, Barry, Michael A. , Koren, Gideon , Odening, Katja E.

Mayo Clinic

Europace | May 24, 2023 | Volume: 25 | Issue: Supplement_1 | Pages: No page available

10.1093/europace/euad122.594 Get It

Abstract Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Pfizer Background Type 1 long QT syndrome (LQT1) is a genetic channelopathy characterized by both haploinsufficient and dominant-negative loss-of-function pathogenic variants in the KCNQ1-encoded Kv7.1 K+ channels conducting IKs. Patients with LQT1 may manifest QT prolongation and ventricular arrhythmias that can culminate in sudden cardiac death. Purpose With this project, we aim to investigate whether our mutation independent, KCNQ1-specific suppression-replacement (SupRep) gene therapy can restore the deficient K+-channel and thereby restore the healthy phenotype. Methods Our proprietary dual component SupRep gene therapy was created by combining a custom-designed KCNQ1 shRNA and a shRNA-immune (shIMM) KCNQ1 cDNA into AAV9. In vivo AAV9-mediated KCNQ1SupRep gene therapy was performed by targeted intra-aortic root construct injection (1E12 vg/kg body weight) during balloon occlusion using a Swan Ganz catheter. 2 weeks after in vivo gene therapy, 12-lead ECGs were assessed in adult transgenic LQT1 (KCNQ1-Y315S, loss-of IKs) and wild-type (WT) rabbits to determine the effect of SupRep therapy on the rabbit’s QTc. Patch-clamp and calcium transient measurements were performed in isolated ventricular cardiomyocytes to evaluate the effect of SupRep on the cardiomyocyte’s action potential duration (APD90) and Ca2+ transient duration (Ca2+90) both, in vitro – after plasmid transfection, and in vivo – after AAV9-mediated gene therapy. AAV9-KCNQ1-construct expression was verified with immunohistochemistry targeting the GFP-tag. Results After injection of 3 LQT1 rabbits so far, no significant changes were observed in the LQT1 rabbits’ QTc before and after in vivo AAV9-mediated gene therapy. However, at the cellular level, LQT1 cardiomyocytes transfected in vitro with the SupRep-plasmid demonstrated a significant reduction of APD90 (ms, 1Hz stimulation at 37°) compared to LQT1 control cells (SupRep-in-vitro, 358±21 vs. control 447±22, p<0.05). No differences were observed between sham-plasmid transfected cardiomyocytes and LQT1 control cells after one day of culturing. Similarly, cardiomyocytes isolated from the 3 LQT1 rabbits that underwent in vivo SupRep gene therapy demonstrated pronounced shortening of both APD90 and Ca2+90 compared to LQT1 controls, leading to levels similar to WT controls (APD90, 1Hz, 37°: LQT1: 530±18, WT: 445±18, LQT1-SupRep: 375±25, p<0.0001 LQT1 vs. LQT1-SupRep, p=ns LQT1-SupRep vs. WT) (Ca2+90: LQT1: 487±23, WT: 346±16, LQT1-SupRep: 393±19, p<0.0001 LQT1 vs. LQT1-SupRep, p=ns LQT1-SupRep vs. WT). Conclusion In vivo KCNQ1-suppression-replacement gene therapy normalizes cellular action potential and calcium transient duration in transgenic LQT1 rabbits. Further in vivo experiments will be conducted to evaluate whether this therapeutic correction at the cardiomyocyte level will translate into normalization of the LQT1 rabbits’ QTc both at rest and during stress testing.
Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction.
Redgrave, Rachael E. , Dookun, Emily , Booth, Laura , Folaranm, Omowumi, Tual‐Chalot, Simon , Passos, João F. , Richardson, Gavin D. , Passos, Joao, Richardson, Gavin D , Passos, João F , Gill, Jason H. , Owens, W. Andrew , Spyridopoulos, Ioakim

Mayo Clinic

No container title available | April 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2776501/v1 | PMID 37090497 Get It

Abstract Myocardial infarction is a leading cause of morbidity and mortality. While reperfusion is now standard therapy, pathological remodeling leading to heart failure remains a clinical problem. Cellular senescence has been shown to contribute to disease pathophysiology and treatment with the senolytic navitoclax attenuates inflammation, reduces adverse myocardial remodeling and results in improved functional recovery. However, it remains unclear which senescent cell populations contribute to these processes. To identify whether senescent cardiomyocytes contribute to disease pathophysiology post-myocardial infarction, we established a transgenic model in which p16 (CDKN2A) expression was specifically knocked-out in the cardiomyocyte population. Following myocardial infarction, mice lacking cardiomyocyte p16 expression demonstrated no difference in cardiomyocyte hypertrophy but exhibited improved cardiac function and significantly reduced scar size in comparison to control animals. This data demonstrates that senescent cardiomyocytes participate in pathological myocardial remodeling. Importantly, inhibition of cardiomyocyte senescence led to reduced senescence-associated inflammation and decreased senescence-associated markers within other myocardial lineages, consistent with the hypothesis that cardiomyocytes promote pathological remodeling by spreading senescence to other cell-types. Collectively this study presents a novel demonstration that senescent cardiomyocytes are major contributors to myocardial remodeling and dysfunction following a myocardial infarction. Therefore, to maximize the potential for clinical translation, it is important to further understand the mechanisms underlying cardiomyocyte senescence and how to optimize senolytic strategies to target this cell lineage.
Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).
Zarif, Talal El , Nassar, Amin, Jiang, Lijuan , Pond, Gregory R. , Zhuang, Tony , Velev, Maud , Álvarez, Pablo, McKay, Rana R. , El‐Am, Edward , Hui, Gavin , Milowsky, Matthew I. , Matthews, Harrison, Sonpavde, Guru , Pond, Gregory Russell , Nassar, Amin H. , Hahn, Andrew W. , Buti, Sebastiano , Vincenzi, Bruno , Lee, Jae‐Lyun , Mouhieddine, Tarek H. , Barata, Pedro C. , Apolo, Andrea B

Mayo Clinic

Journal of Clinical Oncology | March 14, 2023 | Volume: 41 | Issue: 6_suppl | Pages: 5-5

10.1200/jco.2023.41.6_suppl.5 Get It

5 Background: Management options for patients (pts) with advanced (locally advanced or metastatic) PeCa are limited. The GSRGT assembled an international cohort of pts with advanced PeCa treated with ICI to evaluate toxicity and clinical outcomes. Methods: We retrospectively collected data on pts with advanced PeCa receiving ≥1 cycle of ICI between 2015-2022 at 18 medical centers in the US, Europe, and Asia. Immune-related adverse events (irAE) were graded per the Common Terminology Criteria for Adverse Events v5.0. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Objective response rate (ORR) was determined by the clinical investigator per RECIST 1.1 criteria, whenever feasible. Results: Among 72 pts with advanced PeCa treated with ICI, 24 (33%) were Hispanic and 7 (10%) were Black. 60 (83%) pts had metastases while the remainder had locally advanced disease. The median age was 64 (inter-quartile range (IQR): 54,70) years and 48 (67%) had ECOG performance status ≥1. Most pts (n=60, 83%) were treated in the ≥2nd line setting and received pembrolizumab (n=23), nivolumab (n=15), cemiplimab (n=15), nivolumab and ipilimumab (n=7), or other anti-PD1/L1-based therapies (n=12). Among 37 pts with available data on HPV status, 24 (65%) were HPV+. 3 (4%) pts were HIV+. irAE of any grade occurred in 18 (25%) pts, 7 (10%) were grade ≥3, 7 (10%) required steroids, 6 (9%) required hospitalization, and 8 (11%) led to treatment discontinuation. The median OS and 24-month OS and median PFS and 24-month PFS were 9.4 (95%CI: 6.8, 12.8) months and 19.3% (95%CI: 9.2, 32.1) and 2.8 (95%CI: 2.1, 3.9) months and 11.2 % (95%CI: 4.9, 20.2), respectively. Among 66 pts evaluable for response, ORR was 7/66 (11%) (2 with complete response, 5 with partial response), and 16 (24%) pts had stable disease for a disease control rate of 35%. The median duration of response was 7.9 (IQR: 3, not reached) months. Conclusions: In the largest retrospective cohort of ICI-treated advanced PeCa, ICI showed no new safety signals, however, overall anti-tumor activity was limited. Future translational studies are needed to identify pts that are more likely to derive clinical benefit from ICI.
Pedicled Functional Latissimus Flaps for Reconstruction of the Upper Extremity following Resection of Soft-Tissue Sarcomas
Arguello, Alexandra M. , Sullivan, Mikaela H. , Mills, Gavin L. , Moran, Steven L. , Houdek, Matthew T. , Houdek, Matthew T

Mayo Clinic

Current Oncology | March 7, 2023 | Volume: 30 | Issue: 3 | Pages: 3138-3148

10.3390/curroncol30030237 | PMID 36975450 Get It

(1) Background: Resection of soft-tissue sarcomas (STS) of the upper extremity can result in substantial functional impairment with limited options for functional reconstruction. Free functional latissimus flaps have been utilized to restore function of the thigh; however, there is limited data on the use of latissimus flaps for functional reconstruction in the upper extremity. As such, we sought to evaluate our institutional experience with these flaps. (2) Methods: We reviewed ten (seven male; three female; and a mean age of 63 years) patients undergoing soft-tissue sarcoma resection involving the triceps (n = 4), biceps (n = 4), and deltoid (n = 2) reconstructed with a pedicled functional latissimus flap. All surviving patients had at least 1 year of follow-up, with a mean follow-up of 5 years. (3) Results: The mean elbow range of motion and shoulder elevation were 105° and 150°. The mean Musculoskeletal Tumor Society score was 88%, and the muscle strength was four. Four patients had a recipient site wound complication. There were no flap losses. One patient sustained a radiation-associated humerus fracture 5 years postoperatively, treated nonoperatively. (4) Conclusions: Although early complications are high, pedicled functional latissimus flaps allow for wound coverage, potential space obliteration, and restoration of function in the upper extremity following resection of large soft tissue sarcomas.